By Dennis Thompson HealthDay ReporterMONDAY, July 14, 2025 (HealthDay News) — Good news for women of a certain age: Hormone ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Zepbound is a once-weekly injectable weight loss medication that contains tirzepatide as its active ingredient. In 2023, it was approved for use for chronic weight management in adults living with ...

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...